1-4 of 4
Joseph R. Garlich, PhD
Close
Sort by
Journal Articles

SF1126, a Pan-PI3K Inhibitor Has Superior Preclinical Activity to CAL-101 a PI3K Delta-Specific Inhibitor in Aggressive B-Cell Non-Hodgkin's Lymphoma

Daruka Mahadevan, MD, PhD, Wenqing Qi, PhD, Amy Stejskal, MA, Laurence Cooke, BA, Joseph R Garlich, PhD
Journal: Blood
Blood (2011) 118 (21): 2720.
https://doi.org/10.1182/blood.V118.21.2720.2720
Published: 2011
Journal Articles

Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In B-Cell Malignancies.

Joseph R Garlich, PhD, Michael D Becker, Candace F Shelton, Wenqing Qi, PhD, Xiaobing Liu, Laurence Cooke, Daruka Mahadevan, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 1783.
https://doi.org/10.1182/blood.V116.21.1783.1783
Published: 2010
Journal Articles

Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma.

Sagar Lonial, MD, R. Donald Harvey, Pharm, D., Dixil Francis, MPH, Engin Gul, Sundar Jagannath, MD, Sherif Farag, MBBS, PhD, Daniel Hoth, MD, Robert Frumento, M.S., MPH, Joseph R. Garlich, PhD, Suzanne Trudel, MD
Journal: Blood
Blood (2009) 114 (22): 3879.
https://doi.org/10.1182/blood.V114.22.3879.3879
Published: 2009
Journal Articles

SF1126, a Novel PI3K Inhibitor Results in Downstream Inhibition of the PI3K Axis and Displays Sequence Specific Synergy When Combined with Bortezomib in Multiple Myeloma Cells

Ebenezer David, PhD, Xiaodong Peng, PhD, Benjamin G Barwick, Jonathan L Kaufman, MD, Joseph R Garlich, PhD, Sagar Lonial, MD
Journal: Blood
Blood (2008) 112 (11): 5167.
https://doi.org/10.1182/blood.V112.11.5167.5167
Published: 2008